AstraZeneca inks $2bn Treg cell therapy deal with Quell

UK start-up Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases, with an $85 million upfront payment and which

BMS adds to IBD pipeline with $1.9bn GentiBio deal

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).

4th Treg Directed Therapies Summit 2022